Regulation of SIRT1 in Vascular Smooth Muscle Cells from Streptozotocin-Diabetic Rats

Alice Toniolo, Erica Alessia Warden, Alberto Nassi, Andrea Cignarella*, Chiara Bolego
Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

Abstract
Sirtuins enzymes are a conserved family of nicotinamide adenine dinucleotide (NAD)-dependent deacetylases and ADP-ribosyltransferases that mediate responses to oxidative stress, fasting and dietary restriction in mammals. Vascular smooth muscle cells (VSMCs) are involved in many mechanisms that regulate vascular biology in vivo but the role of SIRT1 has not been explored in much detail. Therefore, we investigated the regulation of SIRT1 in cultured VSMCs under various stress conditions including diabetes. Sprague-Dawley rats were made diabetic by injecting a single dose of streptozotocin (65 mg/Kg) and aortic VSMCs were isolated after 4 weeks. Immunocytochemistry showed that SIRT1 was localized predominantly in the nucleus, with lower staining in VSMCs from STZ-diabetic as compared with normoglycemic rats. Previous diabetes induction in vivo and high glucose concentrations in vitro significantly downregulated SIRT1 amounts as detected in Western blot assays, whereas TNF-α (30 ng/ml) stimulation failed to induce significant changes. Because estrogen signaling affects several pathways of oxidative stress control, we also investigated SIRT1 modulation by 17β-estradiol. Treatment with the hormone (10 nM) or a selective estrogen receptor-α agonist decreased SIRT1 levels in VSMCs from normoglycemic but not in those from STZ-diabetic animals. 17β-estradiol treatment also enhanced activation of AMP-dependent kinase, which partners with SIRT1 in a signaling axis. SIRT1 downregulation by 17β-estradiol could be observed as well in human peripheral blood mononuclear cells, a cell type in which SIRT1 downregulation is associated with insulin resistance and subclinical atherosclerosis. These data suggest that SIRT1 protein levels are regulated by diverse cellular stressors to a variable extent in VSMCs from diabetic and normoglycemic rats, warranting further investigation on SIRT1 as a modulator of VSMC activity in settings of vascular inflammation.

Introduction
Vascular aging is characterized by increased oxidative stress and proinflammatory phenotypic alterations. Metabolic stress, such as chronic hyperglycemia in diabetes, is known to increase the production of reacting oxygen species (ROS) and promote inflammatory gene expression, accelerating vascular aging [1]. Vascular smooth muscle cells (VSMCs) are sensitive to inflammatory lesions, and notable responses thereof such as proliferation and migration are accompanied by enhanced expression of proinflammatory cytokines, especially TNF-α. Agents endowed with inhibitory effects on VSMC responses such as those underlying neointima formation may be suitable for intervention in vascular disease [2].

Silent information regulator of gene transcription (SIRT)1 is a prominent member of a family of NAD-dependent enzymes and affects a variety of cellular functions ranging from gene silencing, regulation of cell cycle and apoptosis to energy homeostasis. Use of cell models as well as tissue-specific SIRT1 knockout mice has uncovered potential roles for SIRT1 in disease settings such as diabetes and cardiovascular disease, inflammation, neurodegeneration and cancer [3]. Several recent studies have implicated SIRT1 in the regulation of inflammatory responses. Whereas caloric restriction enhances SIRT1 activity, hyperglycemia induces vascular cell senescence by reducing SIRT1 activity and thereby contribute to the development of diabetic vascular dysfunction. Hyperglycemia decreases SIRT1 expression in cultured endothelial cells [4], whereas overexpression of SIRT1 prevents the hyperglycemia-induced vascular cell senescence and thereby protects against vascular dysfunction in mice with diabetes [4,5]. SIRT1 is expressed not only in the endothelium but also in VSMCs [2,6,7], where it is required for both growth and proliferation, suggesting a potential role of SIRT1 in the control of vascular function under various stress stimuli.

While the preponderance of genetic data indicates that increasing SIRT1 levels or its activity has beneficial physiological effects [8], reports are sometimes conflicting [9]. For instance, the pharmacological inhibition of sirtuin decreased the production of inflammatory cytokines in LPS-stimulated macrophages [10]. In addition, limited information is available as to SIRT1 produced in vascular smooth muscle cells and the modulation thereof by inflammatory and/or metabolic factors. Thus, as SIRT1 appears to be strategically involved in many mechanisms that regulate vascular biology in vivo, objective of this work was to investigate its regulation in cultured VSMCs under various stress conditions. Because a protective role of SIRT1 has been suggested in the...
pathogenesis of diabetic vasculopathy [4,5], we determined SIRT1 levels in VSMCs from normoglycemic and diabetic rats, as well as under inflammatory conditions such as after incubation with the pro-inflammatory cytokine TNF-α. Because of the functional correlation between SIRT1 and estrogen signaling in cancer cells [11], we also assessed SIRT1 modulation by 17β-estradiol in rat VSMCs and, for comparison, in human peripheral blood mononuclear cells (PBMCs), a cell type in which SIRT1 downregulation is associated with insulin resistance and subclinical atherosclerosis [12].

Materials and Methods

Ethics statement

The principles of laboratory care relating to the protection and welfare of vertebrates used for scientific purposes issued by the Directive 2010/63/EU were followed in this study, which was approved by the Institutional Animal Care and Use Committee (CEASA based on the Italian acronym) at the University of Padova. Rats were anesthetized i.v. injection of Zoletil (titelamine HCl and zolazepam HCl) before diabetes induction, and sacrificed under euthanizing pentobarbital (150 mg/kg i.p.) anesthesia.

Diabetes induction

Adult Sprague-Dawley rats weighing 200±14 g (2-months-old) were used for inducing diabetes. The animals were injected i.v. with streptozotocin (STZ) at the dose of 65 mg/kg body weight; control animals were injected with the vehicle and kept in a separate cage. During the 24 hours after the induction, to avoid hypoglycemic crisis, drinking water was substituted with 5% glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, glucose levels in VSMCs from normoglycemic and diabetic rats, as well as under inflammatory conditions such as after incubation with the pro-inflammatory cytokine TNF-α. Because of the functional correlation between SIRT1 and estrogen signaling in cancer cells [11], we also assessed SIRT1 modulation by 17β-estradiol in rat VSMCs and, for comparison, in human peripheral blood mononuclear cells (PBMCs), a cell type in which SIRT1 downregulation is associated with insulin resistance and subclinical atherosclerosis [12].

Materials and Methods

Ethics statement

The principles of laboratory care relating to the protection and welfare of vertebrates used for scientific purposes issued by the Directive 2010/63/EU were followed in this study, which was approved by the Institutional Animal Care and Use Committee (CEASA based on the Italian acronym) at the University of Padova. Rats were anesthetized i.v. injection of Zoletil (titelamine HCl and zolazepam HCl) before diabetes induction, and sacrificed under euthanizing pentobarbital (150 mg/kg i.p.) anesthesia.

Diabetes induction

Adult Sprague-Dawley rats weighing 200±14 g (2-months-old) were used for inducing diabetes. The animals were injected i.v. with streptozotocin (STZ) at the dose of 65 mg/kg body weight; control animals were injected with the vehicle and kept in a separate cage. During the 24 hours after the induction, to avoid hypoglycemic crisis, drinking water was substituted with 5% glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl).

Diabetes induction

Adult Sprague-Dawley rats weighing 200±14 g (2-months-old) were used for inducing diabetes. The animals were injected i.v. with streptozotocin (STZ) at the dose of 65 mg/kg body weight; control animals were injected with the vehicle and kept in a separate cage. During the 24 hours after the induction, to avoid hypoglycemic crisis, drinking water was substituted with 5% glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl).

Diabetes induction

Adult Sprague-Dawley rats weighing 200±14 g (2-months-old) were used for inducing diabetes. The animals were injected i.v. with streptozotocin (STZ) at the dose of 65 mg/kg body weight; control animals were injected with the vehicle and kept in a separate cage. During the 24 hours after the induction, to avoid hypoglycemic crisis, drinking water was substituted with 5% glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl). Diabetes induction. At sacrifice 4 weeks after STZ injection, glucose solution. Four days later glycosuria was tested to confirm diabetes induction. At sacrifice 4 weeks after STZ injection, animals had plasma glucose levels above 25 mM (300 mg/dl).
immunoglobulin antibody. Specific proteins were detected using enhanced chemiluminescence (ECL1 and ECL2, GE Healthcare). Band intensities were quantified by densitometry and the results were normalized to β-actin (specific antibody diluted 1:5000, Sigma-Aldrich).

Statistical analysis
Results were expressed as the mean ± SEM of multiple independent experiments for in vitro assays. The Student t test was used to compare 2 groups or ANOVA (2-tailed probability value) was used with the Dunnett post hoc test for multiple groups using GraphPad Instat 3 software (San Diego, CA). The level of statistical significance was 0.05.

Results

Diabetes induction by streptozotocin
Four weeks after STZ injection, diabetic animals had blood glucose 593 ± 14 mg/dl (animals were considered diabetic when blood glucose exceeds 300 mg/dl) and weighed 185 ± 8 g; in contrast, control animals had significantly lower of blood glucose levels (113 ± 7 mg/dl) and higher body weight (350 ± 22 g) as compared with diabetic animals (Fig. 1).

SIRT1 detection and localization in VSMCs
Once ascertained the purity of VSMC cultures using α-actin immunohistochemistry (data not shown), the presence and localization of SIRT1 was investigated. VSMCs from normoglycemic and diabetic rats were probed with a rabbit antibody for SIRT1 and then all incubated with a secondary anti-rabbit antibody conjugated to phycoerythrin. While SIRT1 was found to be prevalently localized in the nucleus, labeling appeared to be weaker in VSMCs from diabetic (Fig. 2D) as compared with control rats (Fig. 2B). This was confirmed by densitometric analysis of replicate images (Fig. 2E).

Diabetes and high glucose downregulate SIRT1 protein
The aim of these experiments was to assess the effects of exposure to high glucose concentrations on the amount of SIRT1 protein both in the ex vivo STZ model and in vitro to dissect potential differential contributions of the diabetic condition in toto as opposed to the leading hyperglycemic status. As shown in Fig. 3A, levels of SIRT1 in diabetic VSMCs were significantly lower than in normoglycemic VSMCs. A similar experiment was performed in normoglycemic VSMCs in the presence of high concentrations (22.2 mM) of D-(+)-glucose, L-(−)-glucose and mannitol. As shown in Fig. 3B, incubation with D-(+)-glucose downregulated SIRT1 levels to a similar extent as that seen in diabetic VSMCs. Whereas the inactive isomer L-(−)-glucose did not affect SIRT1 levels, mannitol unexpectedly reduced SIRT1 levels and therefore may not be regarded simply as an osmotic control in this experiment design.

SIRT1 modulation by TNF-α
In previous studies, the pro-inflammatory cytokine TNF-α was shown to upregulate SIRT1 expression in a time-dependent manner in VSMCs [17]. We repeated this experiment in both VSMC groups. In our hands, no significant changes in SIRT1 protein levels were observed in response to TNF-α stimulation in normoglycemic and diabetic VSMCs at different time points (Fig. 4).

Effects of 17β-estradiol on SIRT1 levels in different cell types
Based on previous studies from our group [14,15] showing that the anti-inflammatory activity of 17β-estradiol is impaired in VSMCs from diabetic rats, we tested the hypothesis that SIRT1 could be a downstream target of the hormone in vascular cells. In normoglycemic VSMCs, incubation with 10 nM 17β-estradiol led to diminished SIRT1 accumulation during the time course (Fig. 5). Consistent with the findings shown in Figs 2 to 4 above, SIRT1 protein amount was lower in diabetic than in normoglycemic VSMCs at baseline. Conversely, 17β-estradiol did not induce further changes in SIRT1 protein amounts in diabetic VSMCs as compared with baseline (Fig. 5). 17β-estradiol is a nonselective estrogen receptor (ER) agonist. Therefore, to explore the estrogen signaling pathways involved in SIRT1 modulation, we performed experiments using the selective ERα agonist PPT and the selective ERβ agonist DPN. As shown in Fig. 6, treatment with PPT for 6 h and 24 h reduced SIRT1 levels in normoglycemic but not in diabetic VSMCs. By contrast, treatment with DPN had no effect on SIRT1 in normoglycemic VSMCs, whereas it increased SIRT1 levels in diabetic VSMCs after 6 h treatment, suggesting that 17β-estradiol modulated SIRT1 abundance mainly through ERα signaling.

Because a close interplay between SIRT1 and AMP-activated protein kinase (AMPK) has been described in the regulation of cellular metabolism and inflammation [18], and because 17β-estradiol regulates the functional expression of AMPK [19], we measured the total expression and phosphorylation level of AMPK. The pAMPK to AMPK ratio was significantly reduced in VSMCs from diabetic as compared with normoglycemic
animals (Fig. 7), in agreement with previous studies [20]. After treatment with 17β-estradiol, the total expression of AMPK remained unaltered, whereas levels of pAMPK were significantly increased by 17β-estradiol in both VSMC groups (Fig. 7). Thus, 17β-estradiol–mediated SIRT1 downregulation was associated with increased AMPK activation.

Finally, we tested whether the above pattern of SIRT1 regulation by 17β-estradiol could apply to human cells. As a test model we chose PBMCs in view of the association between Sirt1 gene expression in this cell type and metabolic control [12]. Incubation with 17β-estradiol for 24 h significantly reduced SIRT1 protein amounts in human PBMCs (Fig. 8). While the trend was similar, changes in SIRT1 in response to treatment with 10 nM dexamethasone, a well-established anti-inflammatory agent, did not achieve statistical significance.

**Discussion**

SIRT1 plays an important role in many pathophysiological processes, including cellular senescence/aging and inflammation [3, 21], yet the precise role of SIRT1 in oxidative stress remains enigmatic. Studies in multiple organs and cell systems hint that SIRT1 depletion could be an adaptive mechanism to promote oxidative stress resistance. However, loss of SIRT1 was also interpreted to contribute to the detrimental effects of oxidative stress [22, 23]. Some of the seemingly conflicting results that have
been reported may be attributable to an optimal window for SIRT1 activity, as has been observed for oxidative stress levels in the heart [24]. At the same time, amelioration of oxidative stress in other cell types and organs suggests that SIRT1 activation could have a real therapeutic benefit under conditions of excessive ROS production. There is evidence that SIRT1 can suppress ROS generation by virtue of its anti-inflammatory actions. NAD(P)H oxidase is an important producer of ROS in vivo, and SIRT1 can inhibit production of an upstream signal, TNF-α, through deacetylation and inhibition of nuclear factor (NF)-κB in macrophages [25]. By contrast, the pharmacologic inhibition of sirtuins has also been reported to inhibit the activation of the NF-κB pathway and decrease the production of LPS-induced cytokines in J774 macrophages in vitro [10]. Our TNF-α stimulation experiments in VSMCs yielded no hint of SIRT1 modulation, in contrast to findings by Zhang and coworkers [17]. The discrepancy may be due to variability in cell culture conditions and/or TNF-α bioactivity compared with those of Zhang et al. It is however possible that other inflammatory stimuli combined with TNF-α induce upregulation of SIRT1, which may be part of a protective response of VSMCs to inflammatory events.

In agreement with previous studies in human endothelial cells and STZ-diabetic mice [4], SIRT1 accumulation fell in diabetic compared to normoglycemic VSMCs, as confirmed using two different experimental procedures, and our in vitro high glucose studies are consistent with this pattern. To the best of our knowledge, this is the first demonstration of reduced SIRT1 levels in aortic VSMCs from STZ-diabetic rats. SIRT1 is also an important regulator of macrophage inflammatory responses in the context of insulin resistance [26]. Because SIRT1 requires NAD for its enzymatic activity [27], a decline in NAD biosynthesis on high glucose or hyperglycemia may result in a significant reduction of SIRT1 levels and subsequent loss of the glucose- or insulin-responsive phenotypes. Accordingly, a significant reduction in NAD+ levels and SIRT1 activity in physiologically aged female Wistar rats has been recently reported [28]. Similarly, although estrogen has been shown to inhibit VSMC proliferation under normal glucose concentrations, high glucose conditions abolist the antiproliferative effect of estrogen through as yet unknown mechanisms [29].

The relationship between SIRT1 and estrogen signaling is still controversial. In particular, it is unclear whether SIRT1 actually serves as an estrogen receptor (ER) co-activator or co-repressor in oncogenesis [11,30]. To the best of our knowledge, we here report for the first time that 17β-estradiol reduced the expression of SIRT1 in normoglycemic VSMCs, and did so in human PBMCs.

Figure 4. SIRT1 modulation under inflammatory stimulus by TNF-α. VSMCs from normoglycemic and STZ-diabetic rats were incubated with 30 ng/ml TNF-α for the indicated times; the amount of SIRT1 at baseline in normoglycemic VSMCs was taken as 100%. A representative Western blot is shown. Values are mean ± SEM (n = 6). *p<0.05, **p<0.01 vs control.
doi:10.1371/journal.pone.0065666.g004

Figure 5. Effect of 17β-estradiol on SIRT1 levels in VSMCs. VSMCs from normoglycemic and STZ-diabetic rats were incubated with 10 nM 17β-estradiol for 0, 6 and 24 h in 2% FBS phenol-red free culture medium, to avoid any interference from the weak estrogenic agent phenol red. SIRT amounts in normoglycemic VSMCs at baseline were taken as 100%. A representative Western blot is shown. Values are mean ± SEM (n = 6). *p<0.05, **p<0.01, ***p<0.001 vs control.
doi:10.1371/journal.pone.0065666.g005

Figure 6. Effect of the selective ERα agonist PPT and the selective ERβ agonist DPN on SIRT1 levels in VSMCs. VSMCs from normoglycemic and STZ-diabetic rats were incubated with PPT or DPN (0.1 μM) for 0, 6 and 24 h in 2% FBS phenol-red free culture medium, to avoid any interference from the weak estrogenic agent phenol red. SIRT amounts in normoglycemic VSMCs at baseline were taken as 100%. A representative Western blot is shown. Values are mean ± SEM (n = 3). *p<0.05 vs control.
doi:10.1371/journal.pone.0065666.g006
As well, whereas it did not appear to affect SIRT1 protein amounts in diabetic VSMCs. SIRT1 downregulation was mimicked by the selective ER\(\alpha\) agonist PPT, but not the selective ER\(\beta\) agonist DPN, which in turn increased SIRT1 abundance after short-term incubation in VSMCs from diabetic animals. Previous studies from our laboratory showed that VSMCs from STZ-diabetic rats overexpress ER\(\beta\) compared with normoglycemic animals [15]. This is associated with impaired downregulation of the inflammatory enzyme inducible NO synthase by 17\(\beta\)-estradiol [15]. Thus, ER\(\alpha\) and ER\(\beta\) appear to differentially regulate SIRT1, consistent with a yin-yang action pattern in tissues where both isoforms are co-expressed and with a recent study showing that SIRT3 protein levels are affected by the ER\(\alpha\)/ER\(\beta\) ratio in breast cancer specimens [31]. In addition, SIRT1 has been described to reverse the acetylation of ER\(\alpha\) [32] and thereby reduce its transcriptional activity, although the relevance of this mechanism was not tested in the present study. A potential involvement of GPER, a non-genomic mediator of estrogen action expressed in VSMC [33], in SIRT1 modulation by 17\(\beta\)-estradiol remains to be determined.

An additional finding from the present study is that 17\(\beta\)-estradiol treatment enhanced AMPK activation in VSMCs from normoglycemic and reversed the significant impairment of AMPK activity in those from diabetic animals compared with controls, in line with previous studies [20]. It cannot be ruled out that the discordant modulation of SIRT1 and AMPK proteins by 17\(\beta\)-estradiol in VSMCs occurred through independent mechanisms. However, 17\(\beta\)-estradiol is a known activator of AMPK [19], and non-concomitant regulation of AMPK activity and SIRT1 abundance has been reported in different tissues [34–36]. Thus, 17\(\beta\)-estradiol-mediated SIRT1 downregulation may be a potential downstream effect of AMPK activation resulting from amelioration of oxidant burden or changes in energy state [18,36].

In conclusion, the present study shows that previous diabetes induction in vivo negatively regulated SIRT1 amounts in rat VSMCs, consistent with the in vivo effects of high glucose concentrations, whereas we were unable to demonstrate SIRT1 modulation by TNF-\(\alpha\). In addition, 17\(\beta\)-estradiol decreased SIRT1 levels in VSMCs from normoglycemic but not diabetic rats most likely through ER\(\alpha\) signaling, possibly as a downstream effect of AMPK activation. This negative regulation of SIRT1 could also be observed in human cell types, namely PBMCs freshly isolated from buffy coat, suggesting that findings in the rodent cell model can be translated to human settings. Whether the observed changes in SIRT1 protein levels in VSMCs are paralleled by changes in protein deacetylase activity remains to be determined. Future studies should also explore how the different levels of the SIRT1 regulatory network are connected in response to diverse cellular stressors, and what balances the net SIRT1 activity [9].

Author Contributions
Conceived and designed the experiments: AC CB. Performed the experiments: AT EAW AN CB. Contributed reagents/materials/analysis tools: AC CB. Wrote the paper: AC.

References
1. Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A. (2010) Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 65: 1028–1041.
2. Li L, Zhang HV, Chen HZ, Gao P, Zhu LH, et al. (2011) SIRT1 acts as a modulator of neointima formation following vascular injury in mice. Circ Res 108: 1180–1189.
3. Guarante L. (2011) Franklin H. Epstein Lecture: Siruatins, aging, and medicine. N Engl J Med 364: 2235–2244.
4. Orimo M, Mimamino T, Miyachi H, Tateno K, Okada S, et al. (2009) Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 29: 809–894.
5. Banks AS, Kon N, Knight C, Matsumoto M, Gu ´errez-J ´uarez R, et al. (2008) Sir21 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8: 333–341.
Maggi A, Cignarella A, Brusadelli A, Bolego C, Pinna C, et al. (2003) Diabetes
Zancan V, Santagati S, Bolego C, Vegeto E, Maggi A, et al. (1999) 17
Wei M, Ong L, Smith MT, Ross FB, Schmid K, et al. (2003). The
de Kreutzenberg SV, Ceolotto G, Papparella I, Bortoluzzi A, Semplicini A, et al.
Moore RL, Dai Y, Faller DV. (2012) Sirtuin 1 (SIRT1) and steroid hormone
Fernandes CA, Fievez L, Neyrinck AM, Delzenne NM, Bureau F, et al. (2012)
Zhang HN, Li L, Gao P, Chen HZ, Zhang R, et al. (2010) Involvement of the
Idel S, Ellinghaus P, Wolfrum C, Nofer JR, Gloerich J, et al. (2002) Branched
Schulz E, Anter E, Zou MH, Keaney JF Jr. (2005) Estradiol-mediated
Schulz EK, Nelson L, Caccavo JM, Saha AK, et al. (2010) AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab 298: E751–E760.
Schulz E, Anter E, Zou MH, Keaney JF Jr. (2005) Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation 111: 3473–3480.
Ning J, Xi G, Clemmons DR. (2011) Suppression of AMPK activation via S485 phosphorylation by IGF-1 during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology 152: 3143–3154.
Yao H, Rahman I. (2012) Perspectives on translational and therapeutic aspects of SIRT1 in inflammmaging and senescence. Biochem Pharmacol 84: 1332–1339.